在复发性多重体炎和性结肠炎重叠的情况下,对戈利穆马布的成功反应
Shu Kojima1, Satohiro Matsumoto1, Yudai Koito1
1Department of Gastroenterology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Biologics : targets & therapy
|January 18, 2024
概括
这项案例研究突出了复发性多重体炎 (RP) 和性结肠炎 (UC) 的罕见重叠. 有效的管理涉及类固醇和抗TNF疗法,导致症状解决.
科学领域:
- 胃肠病学 胃肠病学
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病.
- 肠外表现 (EIM) 在UC中很常见,但心周溢出是罕见的.
- 复发性多合体炎 (RP) 是一种罕见的自身免疫性疾病,影响软骨.
研究的目的:
- 报告一次性复发性多合体炎 (RP) 病例,使性结肠炎 (UC) 的复发复杂化.
- 讨论这种罕见的共同发生的诊断挑战和治疗策略.
- 强调识别非典型UC表现的重要性.
主要方法:
- 一名51岁的男性有UC病史,出现了暗示UC复发和肠外并发症的症状.
- 诊断工作包括对UC复发和RP标准进行临床评估.
- 治疗涉及初始类固醇治疗,随后是使用抗TNF-α抑制剂戈利穆马布的维护治疗.
主要成果:
- 该患者经历了UC复发,出现了不典型的症状,包括心周溢血.
- 确立了复发性多合体炎 (RP) 与UC重叠的诊断.
- 使用类固醇和戈利穆马布的联合治疗导致症状完全消失,UC和RP的缓解.
结论:
- 这一案例表明,性结肠炎和复发性多重体炎之间存在罕见但显著的关联.
- 及时诊断和多方面的治疗方法,包括抗TNF疗法,可以有效地管理这种复杂的疾病.
- 需要进一步的研究来建立UC-RP重叠综合征的治疗方案.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139
Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Inflammatory Bowel Disease V: Surgical Management
147
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
147
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


